Reasons to Retain TNDM Stock in Your Portfolio for Now

Zacks01-21

Tandem Diabetes Care, Inc.’s TNDM impressive strategic initiatives are expected to bolster growth in the upcoming quarters. A robust diabetes market provides a favorable opportunity for the company’s ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2505863222?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-21 19:07","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2505863222","market":"us","top_or_hot":-1,"title":"Reasons to Retain TNDM Stock in Your Portfolio for Now","media":"Zacks","content":"<div>\n<p>Tandem Diabetes Care, Inc.’s TNDM impressive strategic initiatives are expected to bolster growth in the upcoming quarters. A robust diabetes market provides a favorable opportunity for the company’s ...</p>\n\n<a href=\"https://finance.yahoo.com/news/reasons-retain-tndm-stock-portfolio-110700158.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Reasons to Retain TNDM Stock in Your Portfolio for Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nReasons to Retain TNDM Stock in Your Portfolio for Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-21 19:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/reasons-retain-tndm-stock-portfolio-110700158.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tandem Diabetes Care, Inc.’s TNDM impressive strategic initiatives are expected to bolster growth in the upcoming quarters. A robust diabetes market provides a favorable opportunity for the company’s ...</p>\n\n<a href=\"https://finance.yahoo.com/news/reasons-retain-tndm-stock-portfolio-110700158.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TNDM","symbol_name":"糖尿病保健","start_time":0,"source_url":"https://finance.yahoo.com/news/reasons-retain-tndm-stock-portfolio-110700158.html","article_id":"2505863222","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505863222","pubTimestamp":1737457620,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Tandem Diabetes Care, Inc.’s TNDM impressive strategic initiatives are expected to bolster growth in the upcoming quarters. A robust diabetes market provides a favorable opportunity for the company’s growth. However, concerns loom over the adverse impact of macroeconomic challenges. Moreover, the company’s heavy dependence on insulin pumps is worrisome.In the past year, this Zacks Rank #3  company’s shares have surged 44.8% compared with 7.3% growth of the industry and a 24.7% rise of the S&P 500 composite.The renowned medical device company has a market capitalization of $2.31 billion. Tandem Diabetes projects a growth rate of 28.6% for 2025 earnings compared with 18.7% for the S&P 500. TNDM delivered a trailing four-quarter average earnings surprise of 8.28%.Heavy Dependence on Insulin Pumps: Tandem Diabetes generates a large portion of its revenues from the sales of insulin pumps, which accounted for 47% of worldwide sales in the third quarter of 2024. Various factors could adversel","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"TNDM":"糖尿病保健","OMCL":"Omnicell","VCYT":"Veracyte Inc","BK4548":"巴美列捷福持仓","LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","BK4167":"医疗保健技术","BK4082":"医疗保健设备","BK4567":"ESG概念","BK4585":"ETF&股票定投概念","BK4139":"生物科技","RMD":"瑞思迈","BK4588":"碎股","LU2177674079.SGD":"Fidelity Asia Pacific Opportunities A-ACC-SGD (hedged)","BK4504":"桥水持仓"},"translate_title":"目前在您的投资组合中保留TNDM股票的理由","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OMCL":1,"RMD":1,"TNDM":1,"VCYT":1},"content_text":"Tandem Diabetes Care, Inc.’s TNDM impressive strategic initiatives are expected to bolster growth in the upcoming quarters. A robust diabetes market provides a favorable opportunity for the company’s growth. However, concerns loom over the adverse impact of macroeconomic challenges. Moreover, the company’s heavy dependence on insulin pumps is worrisome. \nIn the past year, this Zacks Rank #3 (Hold) company’s shares have surged 44.8% compared with 7.3% growth of the industry and a 24.7% rise of the S&P 500 composite.\nThe renowned medical device company has a market capitalization of $2.31 billion. Tandem Diabetes projects a growth rate of 28.6% for 2025 earnings compared with 18.7% for the S&P 500. TNDM delivered a trailing four-quarter average earnings surprise of 8.28%.\nLet’s delve deeper.\nFactors Benefiting TNDM Stock\nDiabetes Market Boom: An aging population, unhealthy lifestyle, rising awareness and high healthcare expenditures are likely to continue to drive the highly competitive diabetes market. \nIn the near and long term, the company aims to strategically expand the adoption of the insulin pump by type 1 diabetes patients across all its market. The Tandem Diabetes team is actively working with its product launch and commercial strategy to progress in the type 2 diabetes space as well. The Type 2 pivotal study, a randomized controlled trial, is now complete. Additionally, the company had been clinically active throughout 2024, with an extended wear infusion set trial effectively enrolling.\nStrategic Developments Bode Well: Tandem Diabetes seeks to grow its business through the acquisitions of products or technologies or investments in businesses. Last year, it acquired Swiss-based AMF Medical SA — the developer of the Sigi Patch Pump. \nThe company’s speed-to-market with CGM integrations gives it a competitive advantage as its CGM partners advance and drive the adoption of sensor technology. This is evident from G7 and G6, Dexcom’s CGM systems that Tandem Diabetes has integrated with its pump technology, along with Abbott’s latest CGM innovation. In the third quarter of 2024, t:slim X2 became compatible with Eli Lilly and Company’s Lyumjev — an ultra-rapid-acting insulin in the European Union. \nIn addition, the company made a distribution-centric transition in the first half of 2023 to create long-term efficiency for its European operations. Other strategic initiatives include driving operational cost savings across all products and processes through lean activities and other manufacturing efficiencies.\nFactors Weighing on TNDM Stock\nHeavy Dependence on Insulin Pumps:  Tandem Diabetes generates a large portion of its revenues from the sales of insulin pumps, which accounted for 47% of worldwide sales in the third quarter of 2024. Various factors could adversely affect the market acceptance of the company’s products, such as challenges in gaining widespread acceptance among people with insulin-dependent diabetes, their caregivers, healthcare providers and key opinion leaders in the diabetes treatment community. These can potentially hamper the company’s business, financial condition and operating results as well.\nImage Source: Zacks Investment Research\nMacroeconomic Headwinds Persist: The uncertainties related to the current global economic and political conditions would pose challenges for the company. Due to unfavorable general economic conditions, Tandem Diabetes’ profitability could decline and affect its overall financial performance. In the third quarter of 2024, the cost of sales increased 24.5% from the prior-year level. \nEstimate Trend\nThe Zacks Consensus Estimate for 2024 loss per share has remained unchanged at $1.68 in the past 30 days. \nThe Zacks Consensus Estimate for 2025 revenues is pegged at $1.01 billion, which suggests an increase of 10.5% from the year-ago reported number.\nKey Picks\nSome better-ranked stocks in the broader medical space are Veracyte VCYT, Omnicell OMCL and ResMed RMD.\nVeracyte's estimated 2025 earnings growth rate is 65.8% compared with the industry’s 21.9%. Its shares have risen 49.2% in the past year compared with the industry’s 5.5% growth. VCYT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 520.58%. \nVCYT carries a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nOmnicell, carrying a Zacks Rank #2 (Buy) at present, has an earnings yield of 3.7% compared with the industry’s 9.5%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 121.74%. OMCL’s shares have risen 15.2% against the industry’s 16.8% decline in the past year.\nResMed, carrying a Zacks Rank 2 at present, has an estimated earnings growth rate of 8.9% for fiscal 2025. Its shares have surged 33.4% compared with the industry’s 11.1% growth in the past year. RMD’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 6.41%. \nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nOmnicell, Inc. (OMCL) : Free Stock Analysis Report\nResMed Inc. (RMD) : Free Stock Analysis Report\nTandem Diabetes Care, Inc. (TNDM) : Free Stock Analysis Report\nVeracyte, Inc. (VCYT) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2505863222"}